← Leaderboards
Philip Sanderson
National Center For Advancing Translational Sciences
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at National Center For Advancing Translational Sciences
Same institution · by research overlap
Others in their field
Top investigators on “Lead”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Charles Mattias Mountain · Association Of Universities For Research In Astronomy, Inc.$423,098,075
- David Heimbrook · Leidos Biomedical Research, Inc.$406,926,511
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$382,410,253
Research focus
LeadScientistAffectTherapeutics For Rare And Neglected DiseasesIn VivoPreclinical DevelopmentResearch PersonnelPharmaceutical PreparationsDrug KineticsPharmaceutical ChemistryUnited States Food And Drug AdministrationIn VitroLead OptimizationLigamentsEffective TherapyDoseMalariaAntimalarialsAfrica South Of The SaharaMalaria TransmissionBiteDesignDiarrheaHeadache
Grant awards (27)
Antivirals for Rare, Emerging and Endemic RNA Viruses$69,740
ZIA · FY2025 · TR · contact PI
Development of Malaria Transmission-Blocking Drugs$1,897,290
ZIA · FY2022 · TR · contact PI
Antifibrotic Therapy for the Treatment of Pulmonary Hypertension$1,101,796
ZIA · FY2021 · TR · contact PI
Therapy for Fuchs Endothelial Corneal Dystrophy$1,071,030
ZIA · FY2021 · TR · contact PI
Development of Malaria Transmission-Blocking Drugs$1,071,030
ZIA · FY2021 · TR · contact PI
BMP Inhibitors to Treat Fibrodysplasia Ossificans Progressiva$1,071,030
ZIA · FY2021 · TR · contact PI
Therapy for Fuchs Endothelial Corneal Dystrophy$3,726,631
ZIA · FY2020 · TR · contact PI
Development of Malaria Transmission-Blocking Drugs$2,864,330
ZIA · FY2020 · TR · contact PI
BMP Inhibitors to Treat Fibrodysplasia Ossificans Progressiva$1,603,562
ZIA · FY2020 · TR · contact PI
Antifibrotic Therapy for the Treatment of Pulmonary Hypertension$1,593,455
ZIA · FY2020 · TR · contact PI
A Novel Compound for Targeted Treatment of CBF Leukemia$1,469,922
ZIA · FY2020 · TR · contact PI
Therapy for Fuchs Endothelial Corneal Dystrophy$3,240,155
ZIA · FY2019 · TR · contact PI
Development of Malaria Transmission-Blocking Drugs$2,317,870
ZIA · FY2019 · TR · contact PI
BMP Inhibitors to Treat Fibrodysplasia Ossificans Progressiva$948,663
ZIA · FY2019 · TR · contact PI
Antifibrotic Therapy for the Treatment of Pulmonary Hypertension$894,567
ZIA · FY2019 · TR · contact PI
Therapy for Fuchs Endothelial Corneal Dystrophy$3,240,155
ZIA · FY2018 · TR · contact PI
Development of Malaria Transmission-Blocking Drugs$2,317,870
ZIA · FY2018 · TR · contact PI
BMP Inhibitors to Treat Fibrodysplasia Ossificans Progressiva$844,260
ZIA · FY2018 · TR · contact PI
Development of Malaria Transmission-Blocking Drugs$2,453,144
ZIA · FY2017 · TR · contact PI
BMP Inhibitors to Treat Fibrodysplasia Ossificans Progressiva$2,453,144
ZIA · FY2017 · TR · contact PI
Therapy for Fuchs Endothelial Corneal Dystrophy$2,211,853
ZIA · FY2017 · TR · contact PI
Development of Malaria Transmission-Blocking Drugs$1,765,116
ZIA · FY2016 · TR · contact PI
BMP Inhibitors to Treat Fibrodysplasia Ossificans Progressiva$1,765,116
ZIA · FY2016 · TR · contact PI
Development of Malaria Transmission-Blocking Drugs$2,003,778
ZIA · FY2015 · TR · contact PI
BMP Inhibitors to Treat Fibrodysplasia Ossificans Progressiva$2,003,778
ZIA · FY2015 · TR · contact PI
Use of Retinal Progenitor Cells for the Treatment of Retinitis Pigmentosa$695,321
ZIA · FY2015 · TR · contact PI
Deuterated Analogs of Praziquantel for Treatment of Schistosomiasis$139,064
ZIA · FY2015 · TR · contact PI